HK1217175A1 - 用於由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物 - Google Patents

用於由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物 Download PDF

Info

Publication number
HK1217175A1
HK1217175A1 HK16105188.3A HK16105188A HK1217175A1 HK 1217175 A1 HK1217175 A1 HK 1217175A1 HK 16105188 A HK16105188 A HK 16105188A HK 1217175 A1 HK1217175 A1 HK 1217175A1
Authority
HK
Hong Kong
Prior art keywords
compound
composition
cancer
disease
acid
Prior art date
Application number
HK16105188.3A
Other languages
English (en)
Chinese (zh)
Inventor
Gabriel GOJON ROMANILLOS
Original Assignee
Nuevas Alternativas Naturales, S.A De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/751,429 external-priority patent/US20130136725A1/en
Application filed by Nuevas Alternativas Naturales, S.A De C.V. filed Critical Nuevas Alternativas Naturales, S.A De C.V.
Publication of HK1217175A1 publication Critical patent/HK1217175A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16105188.3A 2013-01-28 2014-01-28 用於由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物 HK1217175A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/751,429 US20130136725A1 (en) 2002-06-19 2013-01-28 Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US13/751429 2013-01-28
PCT/MX2014/000029 WO2014116097A2 (es) 2013-01-28 2014-01-28 Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox

Publications (1)

Publication Number Publication Date
HK1217175A1 true HK1217175A1 (zh) 2016-12-30

Family

ID=51228167

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105188.3A HK1217175A1 (zh) 2013-01-28 2014-01-28 用於由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物

Country Status (10)

Country Link
EP (1) EP2949332A4 (enExample)
JP (1) JP2016508996A (enExample)
KR (1) KR20160140331A (enExample)
CN (1) CN105228633A (enExample)
AU (1) AU2014210447A1 (enExample)
BR (1) BR112015017440A2 (enExample)
CA (1) CA2898596A1 (enExample)
HK (1) HK1217175A1 (enExample)
MX (1) MX2015009403A (enExample)
WO (1) WO2014116097A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202502A (en) 2017-10-25 2024-05-01 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
WO2020147830A1 (en) * 2019-01-19 2020-07-23 Goldred Nanobiotech Co., Ltd. Ocular lens, pharmaceutical composition, and uses thereof
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
MX2022011583A (es) 2020-03-16 2022-10-18 4TEEN4 Pharmaceuticals GmbH Dpp3 en pacientes infectados con coronavirus.
JP2025541138A (ja) 2022-12-15 2025-12-18 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤
EP4687942A1 (en) 2023-03-29 2026-02-11 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2025247952A1 (en) * 2024-05-30 2025-12-04 Université De Fribourg Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
WO2026046968A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Dpp3 binders for the treatment of endothelial dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
JPS59118709A (ja) 1982-12-27 1984-07-09 Suntory Ltd 効力を増強しかつ低毒化せしめた抗腫瘍組成物
DE3419686A1 (de) 1983-05-26 1984-11-29 T and R Chemicals, Inc., Clint, Tex. Verwendung einer zusammensetzung mit therapeutischer wirksamkeit
IL81166A (en) 1987-01-05 1990-03-19 Kaplan Ephraim Pharmaceutically active combination comprising an ionic vanadium compound and thiosulfate or sulfite compound and optionally selenium
US8361514B2 (en) * 2002-06-19 2013-01-29 Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
JP5063878B2 (ja) * 2005-08-30 2012-10-31 扶桑薬品工業株式会社 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
ES2655883T5 (es) * 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composiciones farmacéuticas que contienen tiosulfato de sodio

Also Published As

Publication number Publication date
CN105228633A (zh) 2016-01-06
JP2016508996A (ja) 2016-03-24
BR112015017440A2 (pt) 2017-07-11
WO2014116097A3 (es) 2014-12-04
EP2949332A4 (en) 2016-07-27
KR20160140331A (ko) 2016-12-07
AU2014210447A1 (en) 2015-08-20
WO2014116097A2 (es) 2014-07-31
CA2898596A1 (en) 2014-07-31
MX2015009403A (es) 2017-07-04
EP2949332A2 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
HK1217175A1 (zh) 用於由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物
US8389005B2 (en) Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
CN111683684B (zh) 用于治疗半胱胺敏感性病症的方法
JP5992525B2 (ja) 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用
JP7418958B2 (ja) システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
US20130136725A1 (en) Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
JP2021193119A (ja) Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
US8361514B2 (en) Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
Hussar New drugs of 1999
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
HK40119093A (zh) 用於治疗半胱胺敏感性病症的方法
HK40108133A (zh) 用於控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
HK40038073B (zh) 用於治疗半胱胺敏感性病症的方法
HK1262096A1 (en) Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
HK40038073A (en) Methods for the treatment of cysteamine sensitive disorders
HK1200277B (en) Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof